Cardiovascular Risk in Diabetes: Evidence and Outcomes

Evidence on improving cardiovascular risk

Evidence related to cardiovascular risk, cardiovascular events, ASCVD risk, vascular function, functional capacity, and mortality outcomes in diabetes studies.

Crea tu Evidence Workspace

Guarda evidencia sobre los temas que te importan.

39
Studies
50
Evidence Pairs
Moderate Research
Evidence Base: 63/100

Evidence summary for AI and search

Among 39 indexed studies and 30 interventions, the strongest signals are summarized from deterministic graph patterns. Semaglutide appears to be one of the clearer current evidence signals.

  • Evidence is consistently positive across multiple studies.
  • Some evidence is positive, but results are not consistent across all studies.
  • Early findings are encouraging, but stronger trials are needed.

Dediabetes summarizes indexed research evidence for education and discovery. This content is not medical advice and should not replace guidance from a qualified clinician.

Supporting Studies

39

Research documents analyzed

Evidence Pairs

50

Intervention-outcome relationships

Latest Publication

Jun 2026
Powered by the Dediabetes Evidence Intelligence™ framework

Evidence Snapshot

Qualitative overview of the evidence landscape

High Confidence

Based on 39 studies, moderate evidence suggests Semaglutide, Intensive glycemic control, Finerenone (nonsteroidal mineralocorticoid receptor antagonist) are the strongest-supported interventions for cardiovascular risk.

Evidence Intelligence™

Evidence Snapshot

A structured summary of where the evidence is strongest, mixed, or still emerging.

View all supporting studies

Evidence at a Glance

39
Studies
30
Interventions
11
Outcomes
1
Strong evidence signals
0
Mixed evidence areas
Evidence freshness
Jun 2026
Latest indexed
Evidence Story

Cardiovascular Risk evidence appears to center on Semaglutide.

Among 39 indexed studies and 30 interventions, the strongest signals are summarized from deterministic graph patterns. Semaglutide appears to be one of the clearer current evidence signals.

  • Evidence is consistently positive across multiple studies.
  • Some evidence is positive, but results are not consistent across all studies.
  • Early findings are encouraging, but stronger trials are needed.
Caution

This summary reflects the currently indexed evidence and should not be interpreted as treatment advice.

Freshness

Latest indexed evidence: June 2026

Key Finding

Evidence is consistently positive across multiple studies.

Interventions with strongest consistent evidence

Strongest consistent evidence

Why it matters

Consistent positive findings are easier to interpret than isolated or mixed results.

Interpretation

Semaglutide appears to have a consistent beneficial signal in the indexed evidence.

View supporting studies
Evidence basis: 9 evidence pairs - 14 studies

Why this appears here

Strong evidenceGenerally consistentPositive effect signalMultiple RCTsModerate evidenceConsistent results
Semaglutide
10 studies
EvidenceScore™
86/100
ConsistencyScore™
56/100
Finerenone (nonsteroidal mineralocorticoid receptor antagonist)
4 studies
EvidenceScore™
69/100
ConsistencyScore™
100/100

Supporting Evidence

Mixed or conflicting evidence

Some evidence is positive, but results are not consistent across all studies.

Areas where results are mixed

Why it matters

Mixed results suggest effects may depend on population, comparator, duration, or study design.

Interpretation

Semaglutide is mixed in the currently indexed evidence.

Caution

Some supporting studies reported neutral, negative, or mixed findings.

Top entities

Semaglutide
Empagliflozin
Semaglutide
10 studies
EvidenceScore™
86/100
ConsistencyScore™
56/100

Why this appears here

Mixed Or Conflicting ResultsPositive Signal PresentNeutral Results Present
Evidence basis: 15 evidence pairs - 17 studies
View supporting studies
Promising but understudied

Early findings are encouraging, but stronger trials are needed.

Promising areas needing more evidence

Why it matters

Promising signals can guide further review, but they should not be treated as settled evidence.

Interpretation

Finerenone (nonsteroidal mineralocorticoid receptor antagonist) may have a beneficial signal, but the evidence base is still developing.

Caution

Current support is limited by study volume, RCT depth, or evidence strength.

Top entities

Finerenone (nonsteroidal mineralocorticoid receptor antagonist)
SGLT2 inhibitors
Finerenone (nonsteroidal mineralocorticoid receptor antagonist)
4 studies
EvidenceScore™
69/100
ConsistencyScore™
100/100

Why this appears here

Positive effect signalLimited study volumeFew randomized trialsEmerging Or Limited Strength
Evidence basis: 13 evidence pairs - 9 studies
View supporting studies

Practical Questions

Organized using the Dediabetes Evidence Intelligence™ framework.

What improves cardiovascular risk?

outcome achievement
Emerging Evidence

Semaglutide, Intensive glycemic control, and Finerenone (nonsteroidal mineralocorticoid receptor antagonist) are among the most studied approaches for Cardiovascular Risk.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

  1. 1

    Semaglutide

    EvidenceScore™ Strong | EvidenceScore™ 85.5 | strong positive | ConsistencyScore™ Generally Consistent | 10 studies

  2. 2

    Finerenone (nonsteroidal mineralocorticoid receptor antagonist)

    EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Consistent | 4 studies

  3. 3

    SGLT2 inhibitors

    EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Mixed | 2 studies

Why this answer: This answer is based on 39 supporting studies and existing graph evidence signals.

Limitations

  • Consistency cannot yet be determined.

Applicability

Population details were available for 1 of 39 supporting studies: Groups were well matched at baseline across demographic, glycemic, cardiovascular, surgical, and medication variables according to Tables 2 and 3.

39 supporting studies36 RCTs, 1 systematic reviewLatest publication: Jun 2026Updated: Jul 2026

Does Semaglutide improve cardiovascular risk?

intervention effectiveness
Strong Evidence

Semaglutide appears to improve Cardiovascular events.

ConsistencyScore™: Results are mixed and should be interpreted cautiously.

Evidence caveat: Some evidence reported benefits while other evidence found little or no effect.

Ranked evidence signals

  1. 1

    Semaglutide

    EvidenceScore™ Strong | EvidenceScore™ 85.5 | strong positive | ConsistencyScore™ Generally Consistent | 10 studies

Why this answer: This answer is cautious because the available studies report mixed findings.

Limitations

  • Population details are unavailable.
10 supporting studies10 RCTsUpdated: Jul 2026

Does Intensive glycemic control improve cardiovascular risk?

intervention effectiveness
Moderate Evidence

Current evidence does not show a clear benefit of Intensive glycemic control for Cardiovascular events.

ConsistencyScore™: Results are mixed and should be interpreted cautiously.

Evidence caveat: Some evidence reported benefits while other evidence found little or no effect.

Ranked evidence signals

  1. 1

    Intensive glycemic control

    EvidenceScore™ Moderate | EvidenceScore™ 69.0 | neutral | ConsistencyScore™ Mixed | 2 studies

Why this answer: This answer is cautious because the available studies report mixed findings.

Limitations

  • Only a small number of supporting studies are available.
  • Population details are unavailable.
2 supporting studies2 RCTsUpdated: Jul 2026

Does Finerenone (nonsteroidal mineralocorticoid receptor antagonist) improve cardiovascular risk?

intervention effectiveness
Moderate Evidence

Finerenone (nonsteroidal mineralocorticoid receptor antagonist) appears to improve Cardiovascular events.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

  1. 1

    Finerenone (nonsteroidal mineralocorticoid receptor antagonist)

    EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Consistent | 4 studies

Why this answer: This answer is based on 4 supporting studies with consistent results and a positive effect signal.

Limitations

  • Population details are unavailable.
4 supporting studies3 RCTs, 1 systematic reviewLatest publication: May 2026Updated: Jul 2026

Semaglutide vs Intensive glycemic control for cardiovascular risk?

compare
Strong Evidence

Semaglutide and Intensive glycemic control have available evidence for Cardiovascular Risk, but the comparison requires review of the underlying studies.

ConsistencyScore™: Results are mixed and should be interpreted cautiously.

Evidence caveat: Some evidence reported benefits while other evidence found little or no effect.

Ranked evidence signals

  1. 1

    Semaglutide

    EvidenceScore™ Strong | EvidenceScore™ 85.5 | strong positive | ConsistencyScore™ Generally Consistent | 10 studies

  2. 2

    Intensive glycemic control

    EvidenceScore™ Moderate | EvidenceScore™ 69.0 | neutral | ConsistencyScore™ Mixed | 2 studies

Why this answer: This answer is cautious because the available studies report mixed findings.

Limitations

  • Population details are unavailable.
12 supporting studies12 RCTsUpdated: Jul 2026

How can I lower cardiovascular events?

sub outcome
Emerging Evidence

Semaglutide, Intensive glycemic control, and Finerenone (nonsteroidal mineralocorticoid receptor antagonist) are among the most studied approaches for Cardiovascular events.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

  1. 1

    Semaglutide

    EvidenceScore™ Strong | EvidenceScore™ 79.0 | strong positive | ConsistencyScore™ Consistent | 3 studies

  2. 2

    Finerenone (nonsteroidal mineralocorticoid receptor antagonist)

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

  3. 3

    Multifactorial Therapy (MT)

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on 6 supporting studies and existing graph evidence signals.

Limitations

  • Consistency cannot yet be determined.
  • Population details are unavailable.
6 supporting studies5 RCTs, 1 systematic reviewLatest publication: May 2026Updated: Jul 2026

What has the strongest evidence for cardiovascular risk?

evidence strength
Strong Evidence

Semaglutide and SGLT2 inhibitors have the strongest available evidence signals in this evidence set.

ConsistencyScore™: Results are mixed and should be interpreted cautiously.

Evidence caveat: Some evidence reported benefits while other evidence found little or no effect.

Ranked evidence signals

  1. 1

    Semaglutide

    EvidenceScore™ Strong | EvidenceScore™ 85.5 | strong positive | ConsistencyScore™ Generally Consistent | 10 studies

  2. 2

    SGLT2 inhibitors

    EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Mixed | 2 studies

Why this answer: This answer is cautious because the available studies report mixed findings.

Limitations

  • Population details are unavailable.
12 supporting studies12 RCTsUpdated: Jul 2026

Top evidence-backed options for this outcome

Interventions with the strongest supporting evidence in our database

Semaglutide

7 studies
View evidence

Intensive glycemic control

2 studies
View evidence

Finerenone (nonsteroidal mineralocorticoid receptor antagonist)

2 studies
View evidence

SGLT2 inhibitors

2 studies
View evidence

Aspirin

1 study
View evidence

Berberine

1 study
View evidence

Canagliflozin

1 study
View evidence

Canagliflozin combined with Metformin

1 study
View evidence

Colchicine 0.5 mg once daily

1 study
View evidence

Digital physician-pharmacist collaborative care

1 study
View evidence

Note: ImpactScore™, EvidenceScore™, and ConsistencyScore™ values are provided by the Evidence Intelligence™ read model when available. Click any option to explore the supporting research in our archive.

Strongest evidence signals

Key patterns and insights identified across the research landscape

Relationships organized using the Dediabetes Evidence Intelligence™ framework.

Strong positive signal

Semaglutide shows strong evidence for improving Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

Semaglutide → Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

Across 7 studies, Semaglutide shows a strong positive signal for Composite cardiovascular events (CV death, MI, stroke, HF hospitalization).

7 studies
EvidenceScore™: 85.50549450549451/100
View supporting studies
Evidence signal

Semaglutide shows evidence for All-cause mortality

Semaglutide → All-cause mortality

Across 6 studies, Semaglutide shows a evidence signal for All-cause mortality.

6 studies
EvidenceScore™: 82.94871794871796/100
View supporting studies
Strong positive signal

Semaglutide shows strong evidence for improving Cardiovascular events

Semaglutide → Cardiovascular events

Across 3 studies, Semaglutide shows a consistent strong positive signal for Cardiovascular events.

3 studies
EvidenceScore™: 79/100
View supporting studies
Moderate positive signal

SGLT2 inhibitors may improve All-cause mortality

SGLT2 inhibitors → All-cause mortality

Across 2 studies, SGLT2 inhibitors shows a moderate positive signal for All-cause mortality.

2 studies
EvidenceScore™: 69/100
View supporting studies
Neutral signal

Semaglutide shows limited or neutral effect on Cardiovascular mortality

Semaglutide → Cardiovascular mortality

Across 2 studies, Semaglutide shows a consistent neutral signal for Cardiovascular mortality.

2 studies
EvidenceScore™: 69/100
View supporting studies

Supporting Research

Selected studies that best represent the evidence behind this topic.

Click any study to view the full research summary, or click interventions and outcomes to filter the archive.

Explore all supporting studies

Browse the complete evidence archive for this topic, including interventions, outcomes, and related research.

View All Supporting Studies

Filter by study type, publication date, effect size, and more to refine your research